First-pass extracted concept

mTOR/HIF-1α/SIRT1 immunometabolic axis in Hashimoto's thyroiditis

Candidate: concept label1 source documents4 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This pathway concept links increased mTOR/HIF-1α signaling and reduced SIRT1 to metabolic skewing in T cells from patients with HT. The review uses it to explain inflammatory immune polarization.

Source 1DOI PubMed

What problem it solves

It provides a mechanistic bridge between altered metabolism and loss of immune balance in HT.

Source 1DOI PubMed

What it does not solve

The abstract does not establish which node is best to target clinically or how broadly the axis generalizes across autoimmune settings.

Source 1DOI PubMed

Alternatives

The review also mentions broader HIF signaling, antioxidant strategies, and standard levothyroxine treatment as related but distinct approaches.

Source 1DOI PubMed

Evidence Snippets

Increased levels of Mammalian target of rapamycin (mTOR)/HIF-1α and reduced Sirtuin 1 (SIRT1) in T cells from patients diagnosed with HT confirm this metabolic skew.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1review2026MEDDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1mechanistic summarysupports2026Source 1DOI PubMed

Increased mTOR/HIF-1α and reduced SIRT1 in T cells from patients with Hashimoto's thyroiditis are presented as evidence of metabolic skew.

Quoted textsource-backed

Increased levels of Mammalian target of rapamycin (mTOR)/HIF-1α and reduced Sirtuin 1 (SIRT1) in T cells from patients diagnosed with HT confirm this metabolic skew.

Claim 2mechanistic summarysupports2026Source 1DOI PubMed

In Hashimoto's thyroiditis, thyrocyte-derived reactive oxygen species and chronic lymphocytic infiltration stabilize HIF-1α and shift CD4+ T-cell polarity toward Th17 and away from regulatory T cells.

Quoted textsource-backed

In HT, thyrocyte-derived reactive oxygen species and chronic lymphocytic infiltration stabilize HIF-1α, tilting CD4+ T cell polarity towards Th17 and away from regulatory T cells.

Claim 3therapeutic hypothesissupports2026Source 1DOI PubMed

mTOR inhibitors or agents that restore SIRT1 could complement levothyroxine and antioxidant strategies in Hashimoto's thyroiditis.

Quoted textsource-backed

Inhibitors of mTOR or agents that restore SIRT1 could complement levothyroxine and antioxidant strategies.

Claim 4therapeutic hypothesissupports2026Source 1DOI PubMed

The review positions HIF-1α as a therapeutic target in Hashimoto's thyroiditis.

Quoted textsource-backed

Furthermore, the data position HIF-1α as a therapeutic target.